Details of the Drug

General Information of Drug (ID: DM3ADGP)

Drug Name
Rhucin
Synonyms
sildenafil; 139755-83-2; VIAGRA; Sildenafil [INN:BAN]; UK-92480; UNII-3M7OB98Y7H; UK-92,480-10; C22H30N6O4S; HSDB 7305; CHEMBL192; UK 92480-10; CHEBI:9139; 3M7OB98Y7H; 1-((3-(4,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-d)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methylpiperazine; BNRNXUUZRGQAQC-UHFFFAOYSA-N; 5-(2-Ethoxy-5-((4-methylpiperazin-1-yl)sulfonyl)phenyl)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-one; Sildenafil
Indication
Disease Entry ICD 11 Status REF
Erectile dysfunction HA01.1 Approved [1]
Hereditary angioedema 4A00.14 Approved [2]
Affected Organisms
Humans and other mammals
ATC Code
G04BE03: Rhucin
G04BE: Drugs used in erectile dysfunction
G04B: UROLOGICALS
G04: UROLOGICALS
G: GENITO URINARY SYSTEM AND SEX HORMONES
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 474.6
Logarithm of the Partition Coefficient (xlogp) 1.5
Rotatable Bond Count (rotbonds) 7
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 8
Chemical Identifiers
Formula
C22H30N6O4S
IUPAC Name
5-[2-ethoxy-5-(4-methylpiperazin-1-yl)sulfonylphenyl]-1-methyl-3-propyl-6H-pyrazolo[4,3-d]pyrimidin-7-one
Canonical SMILES
CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C
InChI
InChI=1S/C22H30N6O4S/c1-5-7-17-19-20(27(4)25-17)22(29)24-21(23-19)16-14-15(8-9-18(16)32-6-2)33(30,31)28-12-10-26(3)11-13-28/h8-9,14H,5-7,10-13H2,1-4H3,(H,23,24,29)
InChIKey
BNRNXUUZRGQAQC-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
135398744
ChEBI ID
CHEBI:9139
CAS Number
139755-83-2
UNII
3M7OB98Y7H
DrugBank ID
DB00203
TTD ID
D0Z7ZM
VARIDT ID
DR00565
ACDINA ID
D00622
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
C1 esterase inhibitor (SERPING1) TTVQ6R9 IC1_HUMAN Modulator [2]
Phosphodiesterase 5A (PDE5A) TTJ0IQB PDE5A_HUMAN Inhibitor [3]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Angiotensinogen (AGT) OTBZLYR3 ANGT_HUMAN Gene/Protein Processing [4]
Bcl-2-like protein 1 (BCL2L1) OTRC5K9O B2CL1_HUMAN Drug Response [5]
Caspase-9 (CASP9) OTD4RFFG CASP9_HUMAN Drug Response [5]
cGMP-specific 3',5'-cyclic phosphodiesterase (PDE5A) OTT8Q1AP PDE5A_HUMAN Gene/Protein Processing [6]
Cystic fibrosis transmembrane conductance regulator (CFTR) OT6B22QH CFTR_HUMAN Gene/Protein Processing [7]
Cytochrome P450 1B1 (CYP1B1) OTYXFLSD CP1B1_HUMAN Gene/Protein Processing [8]
Natriuretic peptides B (NPPB) OTSN2IPY ANFB_HUMAN Gene/Protein Processing [9]
Renin (REN) OT52GZR2 RENI_HUMAN Gene/Protein Processing [4]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Erectile dysfunction
ICD Disease Classification HA01.1
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Phosphodiesterase 5A (PDE5A) DTT PDE5A 1.60E-01 -0.25 -0.99
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Experimental Cancer Drug Sensitivity Information

Cancer Drug Sensitivity Data Curated from 141 Cell Line(s) in Haematopoietic And Lymphoid Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MEC1 CTRP2 10.6444 12.5797 8.3701 0.8888
JK1 CTRP2 11.1142 13.5226 8.2098 1.0334
JM1 CTRP2 9.792 11.7781 8.2436 2.195
BL-70 CTRP1 5.7481 7.881 4.1726 5.5402
EoL-1 CTRP2 6.409 33.8883 -5.6334 40.6608
BV-173 CTRP2 6.9952 13.2197 5.0767 20.9398
OCI-Ly10 CTRP1 7.2588 11.1634 6.2885 32.255
OCI-AML-3 CTRP2; CTRP1 7.2864 10.9168 6.4252 15.0287
NU-DUL-1 CTRP2; CTRP1 7.7862 11.1083 6.8464 12.0755
KMS-11 CTRP2; CTRP1 7.8138 12.0368 6.4375 13.6604
KMS-34 CTRP2 7.8208 9.9319 7.3957 9.7561
REC-1 CTRP2 7.8938 13.4848 5.808 15.9565
SU-DHL-5 CTRP1 8.1016 8.8034 8.0713 13.8971
Karpas-620 CTRP2 8.1105 11.7231 6.8676 11.1565
KMS-28BM CTRP2 8.1549 12.8602 6.3557 13.1549
KMS-21-BM CTRP2 8.2595 16.2278 4.7826 19.0424
WSU-DLCL2 CTRP2; CTRP1 8.2938 9.4731 8.0831 5.8617
Ku812 CTRP2; CTRP1 8.3808 11.7204 6.5017 6.4733
SKM-1 CTRP2; CTRP1 8.432 12.6954 6.695 11.1977
AMO1 CTRP2; CTRP1 8.4959 9.0769 8.4395 3.9446
Peer CTRP2 8.7275 12.2122 6.5232 5.7463
RPMI-8402 CTRP2 8.7296 11.1018 7.0678 3.3506
P31/FUJ CTRP2 8.7618 10.3846 7.4316 1.7529
KMS-26 CTRP2 8.8036 15.1702 5.7821 14.0954
MC116 CTRP2; CTRP1 8.8677 14.4572 5.5194 9.9057
ST486 CTRP2 8.9007 9.9271 8.4815 2.6925
LP-1 CTRP2; CTRP1 8.9246 11.5118 7.7188 5.8919
SU-DHL-1 CTRP2 8.9583 11.0309 7.2538 2.2256
Mono-Mac-1 CTRP2 8.9843 14.4742 6.2829 11.7116
MOLT-16 CTRP2 8.9877 12.8673 7.0891 8.3568
MHH-CALL-3 CTRP2 8.9887 11.6235 7.7117 5.7416
Mino CTRP2 8.9931 10.5209 8.2665 3.4027
DB CTRP2 9.1149 10.6414 8.3076 2.9953
RPMI-8226 CTRP2; CTRP1 9.127 11.114 8.0875 3.9497
GDM-1 CTRP2; CTRP1 9.1895 13.8186 6.787 9.2807
KMS-20 CTRP2 9.2174 12.4377 7.4934 6.2233
SEM CTRP2 9.256 10.7929 8.3436 2.5927
OCI-AML-2 CTRP2 9.278 10.4838 8.513 1.8518
JJN-3 CTRP2 9.3064 11.6678 7.9481 4.1576
SUP-B15 CTRP2 9.3149 11.6832 7.947 4.1469
MOTN-1 CTRP2 9.421 13.2829 7.2341 6.9408
SET-2 CTRP2 9.4503 11.2041 8.2855 2.5168
KMS-18 CTRP2 9.5011 13.7632 7.0579 7.5342
THP-1 CTRP2; CTRP1 9.5185 13.7054 7.1066 7.35
Kasumi-2 CTRP2 9.6121 13.5405 7.2542 6.5256
NCO2 CTRP2 9.6477 13.7884 7.1584 6.8629
Reh CTRP2 9.6739 12.3947 7.8647 3.8972
PL21 CTRP2; CTRP1 9.6883 16.1606 6.0179 11.5106
SUP-T1 CTRP2 9.7654 12.7899 7.7374 4.2776
MOLM-16 CTRP2; CTRP1 9.771 13.3729 7.4628 5.4475
NU-DHL-1 CTRP2 9.79 11.6975 8.2804 2.053
HD-MY-Z CTRP2 9.8518 13.6231 7.3922 5.5608
L-428 CTRP2 9.8531 11.9596 8.1975 2.2957
RL CTRP2 9.8669 12.9144 7.7489 4.0769
NOMO-1 CTRP2; CTRP1 9.8706 14.3782 7.0417 7.0223
MOLP-8 CTRP2 9.8828 11.8009 8.2911 1.8939
HuT 78 CTRP2 9.8947 13.1019 7.6774 4.3263
Ci-1 CTRP2 9.9738 10.6907 8.8142 0.1244
Karpas-299 CTRP2 9.9904 13.8831 7.3652 5.4555
ME1 CTRP2 10.0003 18.6381 5.0229 14.7261
F-36P CTRP2 10.0168 12.1234 8.2246 1.9857
Daudi CTRP2 10.0174 11.9425 8.3082 1.6701
NB4 CTRP2 10.0241 11.5723 8.4782 1.0506
TF-1 CTRP2 10.1215 12.9783 7.8908 3.1489
HPB-ALL CTRP2 10.1374 15.1487 6.8524 7.3216
OCI-Ly19 CTRP2 10.1383 13.971 7.4267 4.9832
RPMI-6666 CTRP2 10.1689 12.8942 7.9611 2.8126
SUP-T11 CTRP2 10.1711 14.5329 7.1773 5.9464
Raji CTRP2 10.1899 11.8161 8.4615 0.9572
SU-DHL-10 CTRP2 10.2069 21.7761 3.6234 19.0754
P12-Ichikawa CTRP2 10.209 15.3203 6.8203 7.3396
KE-37 CTRP2 10.2611 12.8096 8.0579 2.329
KMS-27 CTRP2 10.2789 14.6031 7.2188 5.6177
SR CTRP2 10.2923 18.2803 5.4248 12.7215
L-363 CTRP2 10.3233 20.4523 4.372 16.4478
Kasumi-1 CTRP2 10.3297 16.3581 6.3997 8.8479
JURL-MK1 CTRP2 10.341 15.0915 7.0256 6.3061
EJM CTRP2; CTRP1 10.3425 14.1621 7.4815 4.5186
TALL-1 [Human adult T-ALL] CTRP2 10.3519 16.1247 6.5301 8.289
OCI-M1 CTRP2 10.3686 15.6169 6.7899 7.2162
DND-41 CTRP2 10.4098 13.8177 7.6816 3.5935
SIG-M5 CTRP2 10.4179 20.5267 4.4078 16.1616
DEL CTRP2 10.4187 11.368 8.7414 0.1185
HL-60 CTRP2 10.4323 12.0728 8.4759 0.7251
U266B1 CTRP2 10.4828 12.6634 8.2512 1.4005
AML-193 CTRP2 10.4836 11.8088 8.6045 0.3564
Ki-JK CTRP2 10.4869 15.5463 6.9073 6.5669
P3HR-1 CTRP2; CTRP1 10.4879 12.8845 8.1569 1.7222
SU-DHL-6 CTRP2 10.501 20.6061 3.6996 14.2938
JeKo-1 CTRP2 10.5049 15.1667 7.1027 5.7577
KMM-1 CTRP2 10.5207 13.695 7.8085 2.9675
MHH-CALL-4 CTRP2 10.5515 11.9953 7.6138 0.107
L-540 CTRP2 10.5626 15.1777 7.1365 5.5412
KHM-1B CTRP2 10.565 18.3185 5.6097 11.5655
EM-2 CTRP2 10.6259 13.169 8.108 1.7584
OCI-AML-5 CTRP2 10.6303 11.5614 8.751 0.067
RS4;11 CTRP2 10.6308 16.4422 6.5739 7.6871
KCL-22 CTRP2 10.6605 12.4533 8.4295 0.7068
U-937 CTRP2; CTRP1 10.6788 15.8047 6.9219 6.2767
SUP-HD1 CTRP2 10.712 13.1946 8.1438 1.5557
JVM-3 CTRP2 10.7139 18.8661 5.45 11.9281
HEL 92.1.7 CTRP2 10.7202 16.9838 6.374 8.3462
MOLM-13 CTRP2 10.7208 15.7884 6.9509 6.0577
KE-97 CTRP2; CTRP1 10.7321 12.4474 8.4647 0.5702
SK-MM-2 CTRP2 10.7599 12.3133 8.529 0.4016
HEL CTRP2 10.7707 11.8736 8.6939 0.1067
Karpas-422 CTRP2 10.7721 13.9197 7.8564 2.5067
EHEB CTRP2 10.7872 12.5147 8.4629 0.5452
CMK CTRP2 10.7875 15.7944 6.9926 5.8008
A4/Fukuda CTRP2 10.8009 13.7479 7.9497 2.1422
PF-382 CTRP2 10.8394 12.4632 8.5055 0.4187
ALL-SIL CTRP2 10.8417 12.5676 8.4662 0.5089
HT CTRP2; CTRP1 10.8803 12.2525 8.6005 0.2162
Ri-1 CTRP2 10.9537 22.2687 3.212 15.2408
CML-T1 CTRP2 10.9729 13.3447 8.2144 1.1187
KYO-1 CTRP2 11.006 12.118 8.6938 0.0699
MM1.S CTRP2 11.0339 20.0752 5.0905 12.7407
Jurkat CTRP2 11.0882 12.4587 8.6057 0.1553
Mono-Mac-6 CTRP2 11.0901 13.6041 7.2434 0.5651
RCH-ACV CTRP2 11.0905 12.9592 8.4226 0.4921
KM-H2 CTRP2 11.1113 12.6371 8.5509 0.2317
Granta-519 CTRP2 11.1436 12.8757 8.4762 0.3563
NCI-H929 CTRP2 11.1629 12.6076 8.581 0.1726
HDLM-2 CTRP2 11.1948 12.993 8.4533 0.3827
Hs 611.T CTRP2 11.2173 12.8855 8.502 0.2831
MV4-11 CTRP2 11.3171 21.5155 4.5907 14.0515
K-562 CTRP2 11.3901 12.9115 8.5582 0.1544
LAMA-84 CTRP2 11.4255 12.9399 8.5612 0.1439
NALM-6 CTRP2 11.4502 20.3438 5.2567 11.4976
MOLM-6 CTRP2 11.4918 20.504 5.2081 11.6108
KMS-12-BM CTRP2 11.631 18.8688 6.089 8.1486
OPM-2 CTRP2 11.7022 39.3707 -3.9608 31.3272
SU-DHL-4 CTRP2; CTRP1 11.7272 20.8909 5.1919 11.3615
MOLP-2 CTRP2 12.2323 22.6705 4.6746 12.396
KO52 CTRP2 12.4635 21.1032 5.5752 8.9373
OCI-Ly3 CTRP2 12.6213 30.7855 0.9958 22.0179
EB1 CTRP2 12.9228 28.2865 2.437 18.1197
Pfeiffer CTRP2 12.928 41.6935 -4.1633 29.9873
M-07e CTRP2 13.1769 26.1869 3.629 14.4126
GA-10 CTRP2 14.3719 35.2393 0.0817 21.5441
SU-DHL-8 CTRP2 14.5362 25.9981 4.5942 9.7331
⏷ Show the Full List of 141 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 24 Cell Line(s) in Oesophagus Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TE15 CTRP2 9.645 11.8103 8.1286 2.8622
TE8 CTRP2 11.2346 25.224 2.7035 19.9828
COLO 680N CTRP2 9.622 11.4487 7.4382 0.8577
OE21 CTRP2 9.9367 11.9839 8.2396 2.0257
OE33 CTRP2 10.0847 18.3304 5.2412 13.7699
TE-14 CTRP2 10.2034 14.1536 7.3836 5.0622
KYSE-30 CTRP2 10.3934 16.3081 6.4704 8.4638
KYSE-450 CTRP2; CTRP1 10.5879 13.9235 7.7444 3.1313
TE-1 CTRP2 10.6256 13.9084 7.7744 2.9734
TE-5 CTRP2 10.8788 13.2479 8.2079 1.2089
KYSE-150 CTRP2 10.9386 12.363 8.5831 0.2283
KYSE-520 CTRP2 10.9754 12.7833 8.4408 0.5038
TE-9 CTRP2 11.0077 12.3825 8.6026 0.1784
KYSE-70 CTRP2 11.1068 20.7071 4.8339 13.5401
TE-10 CTRP2 11.2388 12.8909 8.5085 0.2653
EC-GI-10 CTRP2 11.3686 12.9601 8.5332 0.1925
KYSE-180 CTRP2 11.4404 17.4366 6.6421 6.2966
KYSE-140 CTRP2; CTRP1 11.5961 20.1456 4.6626 9.1153
TE-11 CTRP2 11.6663 19.1216 5.9921 8.4653
TE-4 CTRP2 11.963 30.0297 0.8778 23.2487
KYSE-410 CTRP2; CTRP1 12.5471 22.0117 5.2005 10.1529
OE19 CTRP2 13.7407 24.1073 4.9787 9.4132
TE-6 CTRP2 14.0233 33.9055 0.4834 21.1789
KYSE-510 CTRP2 14.5073 23.7626 5.5898 6.5708
⏷ Show the Full List of 24 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 36 Cell Line(s) in Pancreas Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
N2a-PK1 CTRP2 12.1409 18.5517 6.5611 5.7439
SNU-213 CTRP2 9.3319 16.9153 5.3496 14.7404
HuP-T4 CTRP2; CTRP1 9.4998 13.1266 7.3732 6.2224
KP-2 CTRP2 9.6024 10.8683 8.5495 1.2449
QGP-1 CTRP2; CTRP1 9.65 11.9602 7.2365 1.5131
L3.3 CTRP2 9.7538 11.1292 8.5218 1.1724
YAPC CTRP2 9.7721 11.982 8.1332 2.6607
SW1990 CTRP2 9.8527 11.9684 8.1932 2.3132
PaTu 8988t CTRP2 9.8942 12.0082 8.2012 2.2278
BxPC-3 CTRP2 10.1363 12.7638 7.1456 1.3997
Panc 05.04 CTRP2 10.1966 14.092 7.4087 4.9709
Panc 10.05 CTRP2; CTRP1 10.2835 13.0259 7.9717 2.6299
AsPC-1 CTRP2 10.4641 12.7256 8.2138 1.5465
PaTu 8988s CTRP2 10.5188 12.2919 8.4276 0.8068
PK-45H CTRP2 10.5802 12.2324 8.481 0.615
MIA PaCa-2 CTRP2 10.7067 11.9352 8.648 0.1875
PaTu 8902 CTRP2; CTRP1 10.7475 12.0619 8.6179 0.2267
KP-3 CTRP2; CTRP1 10.8243 12.8368 7.4194 0.3171
SNU-410 CTRP2 10.8295 19.2578 5.3424 12.1437
HPAF-II CTRP2 10.8755 13.2807 8.1924 1.2599
Panc 08.13 CTRP2 10.8876 16.0577 6.9337 5.8959
SUIT-2 CTRP2; CTRP1 10.9046 12.1265 8.6545 0.1296
CFPAC-1 CTRP2; CTRP1 10.9369 13.2323 8.2433 1.0581
Hs 766T CTRP2 11.1031 12.7237 8.5161 0.2946
PSN1 CTRP2 11.1275 13.1932 8.348 0.6518
HuP-T3 CTRP2 11.1671 13.3261 8.3134 0.7179
KP-4 CTRP2 11.1683 12.3078 8.686 0.0576
Panc 02.03 CTRP2 11.262 13.0778 8.4491 0.3661
HPAC CTRP2; CTRP1 11.3635 13.3716 8.3807 0.4658
SU.86.86 CTRP2 12.3489 25.1651 3.5486 15.827
Capan-2 CTRP2; CTRP1 12.4104 19.3659 6.3507 6.1993
Panc 04.03 CTRP2 12.4266 20.6985 5.7418 8.3866
TCC-Pan2 CTRP2 13.8106 24.3452 4.9118 9.5508
Panc 03.27 CTRP2; CTRP1 14.1745 23.2682 5.6209 6.8051
PK-59 CTRP2 14.7026 25.8364 4.7686 8.9998
DAN-G CTRP2 14.8072 31.7647 2.0581 16.5799
⏷ Show the Full List of 36 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 48 Cell Line(s) in Skin Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SH4 CTRP2 10.7883 13.1186 7.3013 0.5642
COLO 741 CTRP1 6.6459 9.2554 4.089 3.9466
CJM [Human melanoma] CTRP2 9.4475 10.8734 8.4444 1.8714
K029AX CTRP2 9.7187 22.1109 3.068 21.6149
G-361 CTRP2; CTRP1 9.7365 16.4219 5.9192 11.772
WM1799 CTRP2 9.7943 16.3162 6.017 11.2803
LOX-IMVI CTRP2 9.7992 11.2509 8.4933 1.2274
IGR-39 CTRP2 9.8306 13.3446 7.5133 5.0964
SK-MEL-2 CTRP2 9.9226 12.4704 8.0008 2.9809
MDA-MB-435S CTRP2 9.9376 11.5848 8.4235 1.333
HMCB CTRP2 10.0419 12.4282 8.0985 2.4394
A-375 CTRP2; CTRP1 10.0905 11.7091 8.4626 1.0804
SK-MEL-28 CTRP2; CTRP1 10.1426 10.8064 8.8453 0.0549
WM793 CTRP2 10.1627 16.194 6.3575 9.2873
Hs 852.T CTRP2; CTRP1 10.2203 16.1552 6.4191 8.9455
SK-MEL-30 CTRP2 10.3573 11.7135 8.586 0.4668
Hs 940.T CTRP2 10.3579 14.6563 7.2476 5.3869
UACC-62 CTRP2 10.371 15.4656 6.8652 6.9088
Hs 294T CTRP2 10.3872 11.5147 8.6756 0.2434
COLO 792 CTRP2 10.4372 14.7605 7.2516 5.2581
COLO 800 CTRP2 10.4495 12.3117 8.3848 0.9901
A2058 CTRP2 10.4594 11.6513 8.654 0.2592
UACC-257 CTRP2 10.5303 14.4222 7.4746 4.2471
RPMI-7951 CTRP2 10.5711 12.0978 8.5304 0.4912
SK-MEL-1 CTRP2; CTRP1 10.5843 11.9294 8.6097 0.324
IGR-37 CTRP2 10.6119 12.1405 8.5318 0.4663
SK-MEL-31 CTRP2 10.6238 14.4573 7.5183 3.956
SK-MEL-3 CTRP2 10.64 11.8906 8.6382 0.2252
A101D CTRP2 10.6746 11.8689 8.6596 0.1777
HT-144 CTRP2 10.7416 12.4627 8.463 0.5695
Hs 936.T CTRP2; CTRP1 10.7444 22.9792 3.442 18.6893
WT2-iPS CTRP2 10.7542 11.858 8.6933 0.1106
WM266-4 CTRP2 10.8217 11.9091 8.7 0.0906
Hs 895.T CTRP2 10.8768 12.5602 8.4843 0.4496
Hs 944.T CTRP2; CTRP1 10.906 14.0469 7.8761 2.2975
MeWo CTRP2 11.0433 14.2508 7.8627 2.2099
WM115 CTRP2 11.1399 12.4696 8.6209 0.1255
Mel JuSo CTRP2 11.1449 16.7975 6.752 6.2598
Mel Ho CTRP2 11.1624 13.127 8.3889 0.5359
IPC-298 CTRP2 11.1735 18.1346 6.1323 8.6225
Hs 688(A).T CTRP2 11.1995 37.4039 -3.378 31.3184
WM88 CTRP2 11.303 12.8379 8.5519 0.1813
IGR-1 CTRP2 11.3347 12.7393 8.5979 0.1177
COLO 829 CTRP2 11.3917 12.9195 8.556 0.1569
SK-MEL-5 CTRP2; CTRP1 12.0268 17.991 6.7569 5.1974
Hs 839.T CTRP2 12.5558 21.6185 5.392 9.4687
RVH-421 CTRP2 13.6426 25.6567 4.1911 12.0733
WM983B CTRP2 14.2367 28.132 3.4079 13.6761
⏷ Show the Full List of 48 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Ascites Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
COLO 684 CTRP2 11.4137 13.7084 8.273 0.688
Cancer Drug Sensitivity Data Curated from 9 Cell Line(s) in Autonomic Ganglia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
Kelly CTRP2 9.4267 13.3092 7.2255 6.9666
SK-N-BE(2) CTRP2 9.5577 14.5347 6.7183 8.8438
KP-N-SI9s CTRP2 9.6275 12.0054 8.0215 3.3258
SK-N-FI CTRP2 10.1131 27.7954 0.5478 26.9097
SK-N-SH CTRP2 10.1642 14.1826 7.3424 5.2865
IMR-32 CTRP2 10.1794 11.3039 8.6677 0.3558
NH-6 CTRP2 10.5302 14.567 7.406 4.5172
CHP-126 CTRP2 10.9839 12.8792 8.4073 0.5799
NB1 CTRP2 11.0412 12.6231 8.5285 0.2926
⏷ Show the Full List of 9 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 6 Cell Line(s) in Biliary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SNU-1196 CTRP2 10.0848 11.3878 7.6558 0.1405
SNU-1079 CTRP2 10.6597 12.4125 7.5084 0.2187
HuCC-T1 CTRP2 10.7535 12.1056 8.6043 0.2494
HuH-28 CTRP2 10.7841 17.7461 6.0486 9.5256
SNU-308 CTRP2 11.1994 12.8352 8.5134 0.2689
SNU-478 CTRP2 11.2757 12.7623 8.5684 0.1649
⏷ Show the Full List of 6 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 15 Cell Line(s) in Bone Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MG-63 CTRP2 9.7863 11.2082 8.5051 1.198
U2OS CTRP2 9.9958 16.6187 6.0219 10.91
Hs 822.T CTRP2 10.1501 10.9394 8.7926 0.1093
SK-ES-1 CTRP2 10.3543 12.4669 8.2669 1.4672
TC71 CTRP2 10.5127 11.5491 8.7124 0.1382
Hs 888.T CTRP2 10.5303 14.9727 7.2128 5.2825
SK-N-MC CTRP2 10.7291 11.7505 8.7214 0.0824
A-673 CTRP2 10.8857 12.2672 8.5973 0.22
SaOS-2 CTRP2 10.9022 16.5787 6.6949 6.8152
CAL-78 CTRP2 11.0834 19.8682 5.2276 12.1647
MHH-ES-1 CTRP2 11.0876 12.9087 8.4406 0.4531
G-292 clone A141B1 CTRP2 11.1199 17.6497 6.3288 7.9395
HOS CTRP2 11.226 12.6404 8.5928 0.1435
SW1353 CTRP2 11.2465 12.5996 8.6143 0.1142
SJSA-1 CTRP2 13.037 32.2517 0.5808 22.3132
⏷ Show the Full List of 15 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 71 Cell Line(s) in Breast Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HCC2218 CTRP2 5.6116 17.004 1.9393 33.7304
MDA-MB-157 CTRP2 7.2784 14.5012 4.7366 21.4722
Hs 578Bst CTRP2 9.1763 15.1179 6.1205 12.0002
HCC1569 CTRP2 9.223 32.2566 -2.4096 33.0913
KPL-1 CTRP2 9.7165 10.506 8.7737 0.3478
MCF-7 CTRP2; CTRP1 9.8675 16.6123 5.9331 11.5304
CAMA-1 CTRP2 9.9556 11.3786 7.6104 0.2467
CAL-120 CTRP2 10.0271 11.3392 8.5804 0.7074
EFM-192A CTRP2 10.0307 12.0628 8.2611 1.8312
ZR-75-1 CTRP2 10.1271 12.4954 8.1206 2.2498
JIMT-1 CTRP2 10.152 11.6511 7.5878 0.2267
CAL-148 CTRP2 10.3255 11.8652 8.5096 0.7005
HCC1143 CTRP2 10.3555 16.9065 6.1494 9.8048
HCC1419 CTRP2 10.4464 12.6834 8.2225 1.533
AU565 CTRP2 10.632 17.3757 6.1205 9.4798
HCC1500 CTRP2 10.6521 13.7038 7.8837 2.5363
HDQ-P1 CTRP2 10.6694 12.2748 8.5047 0.5032
MDA-MB-231 CTRP2 10.6878 17.2316 6.2306 8.9608
HCC1428 CTRP2 10.7098 12.231 8.5392 0.4012
T-47D CTRP2 10.7246 15.262 7.2041 5.0528
BT-474 CTRP2 10.7926 12.204 8.5837 0.2747
Hs 578T CTRP2 10.8401 13.9981 7.8604 2.4208
ZR-75-30 CTRP2 10.851 12.9773 8.3066 0.9314
HMC-1-8 CTRP2 10.8574 20.796 4.6067 14.7367
BT-549 CTRP2 11.0793 12.796 8.4797 0.3738
MDA-MB-468 CTRP2 11.2683 12.7311 8.5766 0.1556
HCC1395 CTRP2 11.4105 17.7207 6.4887 6.9231
HCC1937 CTRP2 11.4728 13.2449 8.4711 0.2599
CAL-51 CTRP2 11.5036 13.2811 8.4699 0.2534
MDA-MB-415 CTRP2 11.5391 19.5413 5.7057 9.7152
HCC1954 CTRP2 11.5961 17.0346 6.9272 5.0242
HCC1806 CTRP2 11.7343 17.0202 7.0174 4.5301
BT-20 CTRP2 11.7632 13.0724 8.6337 0.0415
CAL-85-1 CTRP2 11.764 13.6976 8.42 0.2623
SK-BR-3 CTRP2 12.1525 21.4327 5.2142 10.6389
DU4475 CTRP2 12.397 26.9582 2.7088 18.1587
MDA-MB-453 CTRP2 14.1364 39.6683 -2.2548 25.9108
MDA-MB-361 CTRP2 14.3881 31.1558 2.0671 17.0865
BT 416 CTRP2 9.735 12.8047 7.7083 4.4445
BT 498 CTRP2 10.0265 11.3927 8.5574 0.7819
BT 224 CTRP2 10.2067 11.5445 8.5839 0.5652
BT 216 CTRP2 10.2844 11.8448 8.4978 0.7659
BT 232 CTRP2 10.2967 11.7992 8.5227 0.6818
BT 328 CTRP2 10.3381 11.3253 8.7258 0.1655
BT 422 CTRP2 10.3553 11.722 8.5817 0.4791
BT 444 CTRP2 10.3996 11.4621 8.7001 0.1917
BT 179 CTRP2 10.4162 11.4898 8.6965 0.1928
BT 428 CTRP2 10.4238 11.9456 8.5237 0.5944
BT 112 CTRP2 10.4616 11.5858 8.6793 0.2093
BT 286 CTRP2 10.4635 11.8057 8.597 0.3834
BT 320 CTRP2 10.4871 11.44 8.7414 0.1032
BT164 CTRP2 10.491 11.4144 8.7518 0.0892
BT 271 CTRP2 10.5182 11.9802 8.553 0.4627
BT 159 CTRP2 10.6194 11.9544 8.6062 0.2946
BT 239 CTRP2 10.6204 11.9061 8.6246 0.2575
BT 131 CTRP2 10.6241 11.6683 8.7118 0.1132
BT 340 CTRP2 10.6271 11.545 8.7555 0.0631
BT 333 CTRP2 10.713 11.803 8.6974 0.1136
BT 330 CTRP2 10.7201 11.8035 8.6998 0.1091
BT 504 CTRP2 10.7561 11.8263 8.705 0.0962
BT 245 CTRP2 10.7651 12.343 8.5199 0.4199
BT 440 CTRP2 10.7812 11.9346 8.6764 0.1268
BT147 CTRP2 10.9004 12.3218 8.5832 0.2398
BT 145 CTRP2 11.003 12.3854 8.5998 0.1838
BT 231 CTRP2 11.0871 19.9687 5.1811 12.3281
BT 482 CTRP2 11.0971 12.1541 8.713 0.0451
BT 172 CTRP2 11.1134 12.392 8.6382 0.1102
BT 248 CTRP2 12.3231 23.4553 4.3589 13.318
BT 187 CTRP2 12.4388 19.4728 6.3188 6.2821
BT 139 CTRP2 12.569 19.6522 6.3152 6.1453
BT 228 CTRP2 13.128 23.4762 4.8863 10.4735
⏷ Show the Full List of 71 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Tongue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
YD-38 CTRP2 10.6549 11.9875 8.6084 0.2766
Cancer Drug Sensitivity Data Curated from 42 Cell Line(s) in Central Nervous System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SNU-489 CTRP2 9.2566 11.6796 7.1379 2.3162
SNU-626 CTRP2 9.3229 13.146 6.4904 4.9278
DK-MG CTRP2 9.3511 10.5165 8.5499 1.5859
SNU-1105 CTRP2 9.4616 10.9038 7.5832 0.535
LN-229 CTRP2; CTRP1 9.7262 11.9188 8.1396 2.7477
DBTRG-05MG CTRP2 9.8345 14.7985 6.8003 8.0282
D283 Med CTRP2 9.8487 15.0952 6.6644 8.5626
GMS-10 CTRP2 9.9875 14.4345 7.0934 6.5739
M059K CTRP2 10.2893 13.5426 7.7334 3.5472
TM-31 CTRP2 10.3119 12.4637 8.2446 1.5877
LN-18 CTRP2 10.5319 11.5985 8.7021 0.1491
NMC-G1 CTRP2 10.5384 11.8244 8.6216 0.295
GOS-3 CTRP2 10.5466 14.9927 7.2143 5.2541
SNU-466 CTRP2 10.5758 11.769 8.6573 0.2114
SNU-738 CTRP2 10.5791 11.7321 8.6721 0.1846
Hs 683 CTRP2 10.6341 11.9102 8.6286 0.2449
SF539 CTRP2 10.6358 15.7581 6.9077 6.3493
CCF-STTG1 CTRP2 10.6388 11.413 8.8037 0.0257
U-118MG CTRP2 10.6424 12.2802 8.4904 0.5541
U-87MG ATCC CTRP2 10.7128 11.979 8.6345 0.2085
SW1088 CTRP2 10.7234 15.9666 6.8672 6.3857
CAS-1 CTRP2 10.7685 11.9261 8.6746 0.1319
8-MG-BA CTRP2 10.7758 12.5032 8.4624 0.5525
SNB-75 CTRP2 10.7789 16.1906 6.7974 6.5843
YH-13 CTRP2 10.7849 12.6298 8.4163 0.6667
SF295 CTRP2; CTRP1 10.7987 12.3111 8.5462 0.3476
SNU-201 CTRP2 10.8234 12.0653 8.646 0.1598
GB-1 CTRP2 10.9036 16.5581 6.7056 6.771
ONS-76 CTRP2 11.1979 15.615 7.3378 3.9507
A-172 CTRP2 11.2037 13.6309 8.2082 0.9788
SF268 CTRP2 11.2081 17.4375 6.4896 7.1926
Becker CTRP2 11.2569 12.6987 8.5837 0.1487
42-MG-BA CTRP2 11.6373 18.4433 6.2948 7.3622
SF126 CTRP2 11.7732 19.1826 6.0337 8.1651
T98G CTRP2 11.7857 15.5484 7.6978 2.1015
KNS-81 CTRP2 11.7959 30.4466 0.5449 24.1991
GaMG CTRP2; CTRP1 11.9919 17.5283 6.939 4.5321
KNS-60 CTRP2 12.8347 26.0523 3.4589 15.3943
U-251MG CTRP2 12.9167 20.4924 6.1397 6.3793
KALS-1 CTRP2 13.4315 25.2606 4.2408 12.188
KG-1-C CTRP2 14.33 32.273 1.4898 18.5571
Daoy CTRP2 17.2285 31.3705 3.7434 9.4513
⏷ Show the Full List of 42 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 22 Cell Line(s) in Endometrium Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HEC-151 CTRP2; CTRP1 8.0125 12.2853 6.508 12.9065
JHUEM-2 CTRP2; CTRP1 8.6704 10.7918 7.8506 5.8764
KLE CTRP2; CTRP1 8.8766 13.3687 6.7444 10.0172
JHUEM-7 CTRP2 9.671 11.0723 8.4975 1.3608
HEC-50B CTRP2 10.1695 20.6753 3.4251 15.8127
HEC-1-B CTRP2 10.3045 11.7862 7.5971 0.1734
JHUEM-1 CTRP2 10.4461 12.8831 8.1338 1.8462
EN CTRP2 10.5502 12.5146 8.3504 1.0193
HEC-265 CTRP2; CTRP1 10.5686 11.5892 8.7192 0.1154
MFE-296 CTRP2 10.7172 12.7083 8.3525 0.8895
HEC-59 CTRP2; CTRP1 10.8671 12.6621 8.4406 0.5586
HEC-108 CTRP2; CTRP1 10.989 16.7103 6.6902 6.7126
JHUEM-3 CTRP2 11.0135 22.9111 3.6799 17.5121
HEC-251 CTRP2; CTRP1 11.0159 12.2918 8.6376 0.1288
RL95-2 CTRP2 11.0167 12.9818 8.3816 0.6264
HEC-6 CTRP2; CTRP1 11.0754 12.2621 8.6692 0.0836
ESS-1 CTRP2 11.3653 17.1828 6.7132 6.121
MFE-319 CTRP2; CTRP1 11.7198 17.7113 6.6904 5.7639
EFE-184 CTRP2 11.8733 19.3563 6.0169 8.0947
HEC-1-A CTRP2 12.2807 19.7099 6.1115 7.2259
AN3-CA CTRP2 12.7011 19.6435 6.3978 5.7028
Ishikawa (Heraklio) 02 ER- CTRP2; CTRP1 10.735 11.7053 8.7389 0.0641
⏷ Show the Full List of 22 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 18 Cell Line(s) in Kidney Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
RCC10RGB CTRP2; CTRP1 9.0068 11.7354 7.6769 5.9044
VMRC-RCW CTRP2; CTRP1 9.5087 13.3925 7.2481 6.7287
TUHR10TKB CTRP2 10.2459 11.4198 8.6517 0.3605
TUHR4TKB CTRP2 10.5898 13.8401 7.784 2.979
ACHN CTRP2 10.7123 14.481 7.563 3.6734
TUHR14TKB CTRP2 10.8109 25.5961 2.1947 31.7764
BFTC-909 CTRP2 10.8111 12.1003 8.6287 0.1896
Caki-2 CTRP2 10.8225 12.0573 8.6485 0.1563
KMRC-1 CTRP2 10.8674 12.4644 8.5168 0.3817
KMRC-2 CTRP2 10.9991 12.7898 8.4485 0.475
UO-31 CTRP2 11.0469 18.207 6.0099 9.2792
769-P CTRP2 11.0885 12.5702 8.5662 0.2133
SNU-1272 CTRP2 11.1772 12.7877 8.522 0.2608
Caki-1 CTRP2 11.3277 13.2063 8.428 0.3834
KMRC-20 CTRP2 11.4029 12.8629 8.5797 0.1264
786-O CTRP2 11.5037 17.4943 6.6555 6.1643
OS-RC-2 CTRP2 11.5371 16.8617 6.9707 4.9306
VMRC-RCZ CTRP2 16.2172 29.9208 3.8095 10.2651
⏷ Show the Full List of 18 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 52 Cell Line(s) in Large Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SW403 CTRP1 7.8078 12.2567 3.4104 6.3881
LS180 CTRP2; CTRP1 8.4005 10.3041 7.8285 6.5943
CL-40 CTRP1 8.582 9.3658 8.4314 8.0009
SNU-175 CTRP1 8.5859 9.2207 8.4909 7.4909
SW948 CTRP2; CTRP1 8.5907 10.2795 8.025 5.3377
SNU-81 CTRP1 8.618 9.3271 8.485 7.3455
CW-2 CTRP2; CTRP1 8.6446 10.9879 7.7306 6.4316
CL-34 CTRP1 8.7308 9.2965 8.6164 5.594
SNU-61 CTRP2; CTRP1 8.7323 10.5808 8.0112 5.0726
SNU-C4 CTRP2; CTRP1 8.7628 13.0586 6.8072 10.0354
SK-CO-1 CTRP2; CTRP1 9.069 13.4685 6.1565 6.776
RCM-1 [Human ESC] CTRP2; CTRP1 9.1888 12.6202 7.3853 6.7807
OUMS-23 CTRP2 9.2819 11.007 7.4523 1.0911
GP2d CTRP2; CTRP1 9.5004 11.0139 8.4132 1.9204
SW1417 CTRP2 9.5759 11.8415 8.0645 3.229
CCK-81 CTRP2 9.6341 11.65 8.1986 2.5944
SNU-C1 CTRP2 9.6453 14.6298 6.7393 8.6033
SW620 CTRP2; CTRP1 9.786 12.4332 7.9326 3.4979
SNU-407 CTRP2 9.8069 13.5932 7.3741 5.707
NCI-H747 CTRP2 9.8267 13.938 7.2191 6.3146
DLD-1 CTRP2; CTRP1 9.9018 11.2819 8.5384 0.9589
COLO 320 CTRP2; CTRP1 9.9318 15.4048 6.5808 8.8114
HT-55 CTRP2; CTRP1 9.9387 11.6994 8.3798 1.5354
LoVo CTRP2; CTRP1 9.9651 13.2604 7.6571 4.3516
HT115 CTRP2; CTRP1 9.9952 12.6269 7.9819 3.0039
SNU-1040 CTRP1 9.9963 12.0618 8.2481 4.2143
LS1034 CTRP2 10.1518 12.1409 8.2974 1.5632
COLO 678 CTRP2; CTRP1 10.1611 14.1147 7.3802 5.1849
HT-29 CTRP2; CTRP1 10.3413 11.7227 8.5835 0.5116
SNU-503 CTRP2 10.3566 12.2596 8.3587 1.1526
KM12 CTRP2; CTRP1 10.3633 13.0375 8.0229 2.3853
SW480 CTRP1 10.3766 14.95 7.1261 12.1221
MDST8 CTRP2; CTRP1 10.4008 13.6741 7.7508 3.3804
T84 CTRP2 10.4083 17.3246 5.9828 10.3761
SW48 CTRP2; CTRP1 10.492 19.491 4.2358 12.3465
NCI-H508 CTRP2; CTRP1 10.5261 13.2001 8.0455 2.122
LS513 CTRP2; CTRP1 10.5465 14.5597 7.4201 4.4397
HCC-56 CTRP2 10.5529 11.3998 8.7788 0.0515
SNU-C5 CTRP2; CTRP1 10.6044 12.4967 8.3932 0.8813
HCT 15 CTRP2 10.6174 12.4115 8.4261 0.7441
LS411N CTRP2; CTRP1 10.6444 12.2674 8.4964 0.5376
C2BBe1 CTRP2; CTRP1 10.6731 18.0606 5.8153 10.6031
NCI-H716 CTRP2 10.7103 12.3743 8.4838 0.5337
CL-11 CTRP2 10.7355 18.9823 5.4088 12.0477
COLO205 CTRP2; CTRP1 10.8857 12.4565 8.5274 0.3519
LS123 CTRP2; CTRP1 11.0925 13.8998 8.0494 1.5757
COLO201 CTRP2 11.127 12.5305 8.5949 0.1615
SNU-C2A CTRP2; CTRP1 11.6707 16.179 7.3599 3.3577
HCT 8 CTRP2; CTRP1 11.9072 17.611 6.8589 4.9588
HCT 116 CTRP2; CTRP1 13.076 22.4731 5.3309 9.0626
SW1116 CTRP2 13.1108 30.317 1.5813 19.9853
RKO CTRP2; CTRP1 15.3012 28.2627 4.026 10.645
⏷ Show the Full List of 52 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 20 Cell Line(s) in Liver Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HuH-6 CTRP2 8.7834 15.5726 5.5639 14.9964
Li-7 CTRP2 8.9228 14.4327 6.2519 11.96
SNU-387 CTRP2 9.2838 11.296 8.1153 3.498
SNU-886 CTRP2 9.4683 11.2639 8.2693 5.496
Hep-G2 CTRP2; CTRP1 9.5234 11.9034 8.0028 3.6156
HLF CTRP2 9.741 11.2689 8.4498 1.4582
HuH-1 CTRP2 9.9784 11.7862 8.3562 1.5358
JHH-1 CTRP2 10.0103 18.1537 5.2715 13.7879
SNU-423 CTRP2 10.164 12.0261 8.3556 1.3426
SNU-182 CTRP2 10.372 17.06 6.0862 10.0281
SNU-449 CTRP2; CTRP1 10.452 15.3855 6.9608 6.4033
JHH-6 CTRP2; CTRP1 10.5664 11.312 8.8127 0.0258
JHH-2 CTRP2 10.7769 12.3578 8.5192 0.416
SNU-398 CTRP2; CTRP1 10.8771 12.6086 8.4744 0.4976
SK-HEP-1 CTRP2 11.1632 12.7282 8.538 0.238
Hep 3B2.1-7 CTRP2 11.2028 12.519 8.6264 0.1082
JHH-5 CTRP2 11.2109 12.7483 8.5491 0.2076
JHH-4 CTRP2 11.3481 19.768 5.4643 10.8903
SNU-761 CTRP2 11.4323 28.4565 1.2535 23.2477
PLC/PRF/5 CTRP2 19.9209 52.9345 -4.6274 23.1304
⏷ Show the Full List of 20 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 156 Cell Line(s) in Lung Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NCI-H1930 CTRP1 4.1854 7.8624 2.876 23.0073
HCC33 CTRP1 5.8407 9.116 3.6392 9.7846
COR-L51 CTRP1 6.2024 11.009 5.2551 43.9201
COR-L279 CTRP1 6.442 8.0071 4.5158 1.3641
NCI-H1437 CTRP1 6.6928 9.7318 3.9028 5.2493
RERF-LC-KJ CTRP1 6.7776 8.3154 4.5444 0.8229
NCI-H1048 CTRP1 6.9214 10.3262 3.7678 5.7451
NCI-H1975 CTRP1 7.1483 8.9054 4.4758 0.8082
NCI-H1963 CTRP1 7.2253 14.1188 4.8755 38.1531
COR-L88 CTRP1 7.4043 9.7953 4.2433 1.7011
NCI-H82 CTRP1 7.4946 14.512 2.1756 15.1485
SCLC-21H CTRP1 7.4979 12.0234 6.1359 31.5816
LXF 289 CTRP2; CTRP1 8.3704 12.4881 6.7362 11.1112
NCI-H2073 CTRP1 8.4591 9.6478 8.1849 10.7726
NCI-H1836 CTRP1 8.4655 9.1366 8.3885 9.061
NCI-H3255 CTRP1 8.5215 9.3692 8.366 8.8989
NCI-H2122 CTRP2; CTRP1 8.5275 10.9756 7.6283 7.1172
HCC1833 CTRP2; CTRP1 8.6898 9.4069 8.5273 3.0639
NCI-H1781 CTRP1 8.7486 9.3979 8.5918 5.6993
HCC1359 CTRP1 8.8294 9.5221 8.6163 5.0533
NCI-H1876 CTRP1 8.8784 9.8739 8.4927 5.9033
Sq-1 CTRP2; CTRP1 8.9847 11.8051 7.6234 6.1725
NCI-H2141 CTRP2; CTRP1 9.0146 22.4911 2.3058 25.0401
HCC1195 CTRP2; CTRP1 9.0864 12.7118 7.2553 7.52
NCI-H841 CTRP2; CTRP1 9.2564 11.0483 8.2236 3.1446
NCI-H647 CTRP2 9.2808 13.0424 7.2426 7.1581
EBC-1 CTRP2; CTRP1 9.3261 10.8848 8.3512 2.4438
NCI-H1755 CTRP2; CTRP1 9.3304 11.2534 8.1789 3.204
HCC95 CTRP2 9.4091 11.2166 7.429 1.0582
NCI-H1435 CTRP2; CTRP1 9.4307 16.3346 5.7198 13.1196
NCI-H1184 CTRP2 9.4342 14.7964 6.4903 10.0063
SBC-5 CTRP2 9.5572 10.7714 8.5662 1.2364
T3M-10 CTRP2; CTRP1 9.58 13.5712 7.221 6.7675
NCI-H2023 CTRP2; CTRP1 9.6117 11.2557 8.38 1.9446
SW1271 CTRP2 9.6221 19.6126 4.2375 18.1768
HCC1588 CTRP2 9.6284 19.4857 3.6082 16.1217
LC-1/sq-SF CTRP2; CTRP1 9.6942 11.2001 8.4525 1.505
DMS 53 CTRP2 9.7109 15.2589 6.4775 9.5646
DMS 454 CTRP2 9.7674 16.7585 5.776 12.2824
HCC366 CTRP2 9.7771 12.9001 6.8915 2.6736
NCI-H1341 CTRP2 9.8175 14.8901 6.7422 8.2958
MOR/CPR CTRP2 9.8832 11.8964 8.2466 2.0651
NCI-H2172 CTRP2; CTRP1 9.8846 13.0793 7.6883 4.3446
HCC15 CTRP2; CTRP1 9.8853 14.5691 6.9585 7.3408
DMS 114 CTRP2 9.8895 13.054 7.6971 4.254
COR-L23 CTRP1 9.8903 11.61 8.3916 3.3192
RERF-LC-Ad1 CTRP2 9.9001 10.9304 8.6881 0.4718
NCI-H810 CTRP2; CTRP1 9.9182 14.6591 6.9319 7.3483
NCI-H1105 CTRP2; CTRP1 9.9262 13.8711 7.3317 5.7403
ChaGo-K-1 CTRP2; CTRP1 9.9322 13.949 7.2911 5.8497
HCC2108 CTRP2; CTRP1 9.9547 15.1079 6.7446 8.1043
NCI-H2081 CTRP2; CTRP1 10.0285 12.85 7.8978 3.2926
COLO 668 CTRP2; CTRP1 10.0398 14.2115 7.2403 5.89
DMS 79 CTRP2 10.0706 17.2497 5.7665 11.7877
Lu-99 CTRP2; CTRP1 10.0846 11.6754 8.4662 1.0351
VMRC-LCD CTRP2; CTRP1 10.109 11.7039 8.4669 1.0103
HCC2935 CTRP2; CTRP1 10.1674 14.8496 7.0273 6.609
NCI-H2196 CTRP2 10.1939 12.7974 8.022 2.546
NCI-H2110 CTRP2; CTRP1 10.1962 14.6134 7.1629 6.0137
CAL-12T CTRP2; CTRP1 10.2749 13.4942 7.7543 3.5291
Calu-6 CTRP2; CTRP1 10.3006 16.7291 6.1962 9.7078
NCI-H2170 CTRP2 10.315 12.085 8.4118 1.0134
NCI-H211 CTRP2 10.3318 16.0166 6.5684 8.1665
NCI-H596 CTRP1 10.3382 14.2086 7.4564 9.7003
NCI-H1581 CTRP2 10.3494 15.0561 7.0486 6.2008
NCI-H460 CTRP2; CTRP1 10.3647 11.7103 8.5992 0.4566
NCI-H1573 CTRP2; CTRP1 10.3704 11.8769 8.5264 0.6211
NCI-H2126 CTRP2; CTRP1 10.3705 12.0851 8.4403 0.878
LK2 CTRP2 10.3768 11.0058 8.8501 0.0184
NCI-H2342 CTRP2; CTRP1 10.3905 14.0458 7.5687 4.1071
NCI-H446 CTRP2 10.3908 16.4071 6.4201 8.6697
NCI-H526 CTRP2 10.3943 13.0834 8.0129 2.3449
NCI-H1092 CTRP2 10.4344 15.0345 7.1181 5.797
NCI-H650 CTRP2; CTRP1 10.4376 16.1124 5.8148 6.1679
SW1573 CTRP2 10.4406 13.5719 6.9594 1.7685
NCI-H2286 CTRP2; CTRP1 10.4427 13.1752 7.9999 2.3388
NCI-H196 CTRP2 10.4847 11.8626 8.5841 0.4036
NCI-H1734 CTRP2 10.4955 12.5205 8.3197 1.1615
NCI-H1395 CTRP2 10.505 15.699 6.846 6.7861
HCC827 CTRP2; CTRP1 10.5441 12.4647 8.3766 0.9768
LCLC-97TM1 CTRP2; CTRP1 10.5643 12.6827 8.2862 1.2127
HCC44 CTRP2; CTRP1 10.5998 15.4658 7.0236 5.9388
NCI-H1563 CTRP2 10.6465 12.2344 8.5103 0.5013
HCC4006 CTRP2; CTRP1 10.6528 15.0444 7.2675 4.9438
SK-LU-1 CTRP2; CTRP1 10.6754 15.4987 7.0661 5.7091
NCI-H1155 CTRP2 10.6786 12.2546 8.5166 0.4694
SHP-77 CTRP2; CTRP1 10.7237 12.2275 8.5464 0.3789
NCI-H661 CTRP2; CTRP1 10.7393 12.7614 7.4138 0.3534
NCI-H1651 CTRP2 10.7704 12.7557 8.3587 0.8353
HOP-62 CTRP2 10.8006 16.6745 6.5796 7.415
EKVX CTRP2 10.8255 16.18 6.834 6.3741
NCI-H23 CTRP2; CTRP1 10.8297 15.914 6.9637 5.8566
NCI-H1694 CTRP2; CTRP1 10.8372 12.1847 8.6171 0.2187
NCI-H1373 CTRP2; CTRP1 10.8378 18.2805 5.8264 10.3021
DMS 273 CTRP2; CTRP1 10.85 13.3843 8.1352 1.4641
Calu-3 CTRP2; CTRP1 10.8637 16.6019 6.6576 7.0162
COR-L95 CTRP2 10.8753 13.5533 8.0759 1.6382
NCI-H1339 CTRP2 10.8828 14.5299 7.6448 3.1642
NCI-H2291 CTRP2 10.8946 14.6919 7.5777 3.4011
DV-90 CTRP2; CTRP1 10.9084 12.5499 8.5016 0.3971
NCI-H1793 CTRP2; CTRP1 10.9398 16.3992 6.8058 6.3271
NCI-H2030 CTRP2; CTRP1 10.9503 15.2185 7.3764 4.1404
Lu-65 CTRP2; CTRP1 10.9773 15.9223 7.0565 5.297
NCI-H2228 CTRP2 10.9824 20.8688 4.6634 14.336
NCI-H2085 CTRP2 10.9892 13.7549 8.0493 1.6272
NCI-H292 CTRP2 10.9894 14.425 7.7548 2.6454
NCI-H838 CTRP2 10.9931 12.3544 8.6071 0.1754
HCC2279 CTRP2 10.995 17.6368 6.2494 8.4278
RERF-LC-Ad2 CTRP2 11.0106 12.2649 8.645 0.1206
HARA [Human squamous cell lung carcinoma] CTRP2; CTRP1 11.0151 15.8251 7.1265 4.9771
NCI-H1869 CTRP2 11.1032 12.8354 8.4748 0.3745
NCI-H69 CTRP2 11.117 13.064 8.3937 0.5464
NCI-H322 CTRP2 11.1189 13.1961 8.343 0.6688
LOU-NH91 CTRP2 11.1226 13.1784 8.3516 0.6453
LUDLU-1 CTRP2 11.1607 12.6799 8.5545 0.2125
NCI-H2106 CTRP2 11.1628 13.84 8.1022 1.3193
NCI-H1915 CTRP2; CTRP1 11.1694 15.5756 7.3385 3.9809
A-549 CTRP2; CTRP1 11.1852 16.4938 6.9214 5.5515
NCI-H2029 CTRP2; CTRP1 11.1898 12.3481 8.6799 0.0601
HOP-92 CTRP2 11.2476 17.7554 6.3644 7.6225
NCI-H1838 CTRP2 11.2708 16.9155 6.7781 5.9936
NCI-H522 CTRP2; CTRP1 11.2747 13.1328 8.4338 0.3917
NCI-H2009 CTRP2; CTRP1 11.3058 13.572 8.2786 0.7305
COR-L105 CTRP2 11.3587 14.5674 7.8946 1.8197
LCLC-103H CTRP2; CTRP1 11.4082 17.1411 6.7602 5.8861
SK-MES-1 CTRP2 11.4135 14.2312 8.0633 1.2551
NCI-H889 CTRP2 11.4178 20.9422 4.9429 12.67
NCI-H358 CTRP2; CTRP1 11.451 17.6461 6.5502 6.6342
NCI-H1944 CTRP2; CTRP1 11.4922 13.182 8.5009 0.2096
EPLC-272H CTRP2; CTRP1 11.5028 13.4781 8.3978 0.3788
NCI-H1623 CTRP2 11.5056 13.0599 8.5486 0.1441
NCI-H727 CTRP2; CTRP1 11.5058 18.4858 6.1883 7.9427
HCC1171 CTRP2 11.509 15.2737 7.6695 2.4363
COLO 699 CTRP2; CTRP1 11.5274 15.395 7.6346 2.5761
NCI-H520 CTRP2 11.59 13.1112 8.5612 0.1161
NCI-H1299 CTRP2; CTRP1 11.6182 16.0872 7.371 3.3719
NCI-H2405 CTRP2; CTRP1 11.6188 18.0619 6.4627 6.75
NCI-H1568 CTRP2; CTRP1 11.6282 18.1294 6.4369 6.8354
Calu-1 CTRP2 11.6881 17.8841 6.5901 6.1802
HCC78 CTRP2; CTRP1 11.8066 20.2321 5.5558 9.8902
NCI-H226 CTRP2 11.8522 36.5372 -2.4339 29.1733
NCI-H1355 CTRP2; CTRP1 11.9155 19.7162 5.8742 8.5685
NCI-H441 CTRP2; CTRP1 12.0132 16.8766 7.251 3.438
NCI-H1792 CTRP2; CTRP1 12.1601 19.8559 5.9668 7.9074
BEN CTRP2; CTRP1 12.311 23.3803 4.3867 13.2442
HCC1438 CTRP2 12.3427 19.2159 6.3785 6.1768
NCI-H2087 CTRP2 12.371 32.7872 -0.1775 24.764
PC-14 CTRP2 12.4072 26.1539 3.1087 17.0299
NCI-H1703 CTRP2 12.6946 21.5996 5.4901 8.9446
RERF-LC-MS CTRP2 12.8435 21.5548 5.6052 8.3538
NCI-H1650 CTRP2 12.8606 20.1837 6.2468 6.063
NCI-H2444 CTRP2 13.3528 38.1409 -2.0839 26.6445
KNS-62 CTRP2; CTRP1 13.3806 20.6086 6.3559 5.142
RERF-LC-A1 CTRP2 13.4456 23.8972 4.8917 10.0576
NCI-H1666 CTRP2; CTRP1 14.7963 28.2417 3.7156 12.102
Hs 888.Lu CTRP2 10.0416 12.448 8.0891 2.4765
⏷ Show the Full List of 156 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 45 Cell Line(s) in Ovary Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
2004 CTRP2 9.3448 12.7177 7.4556 6.1506
COV318 CTRP1 6.5619 7.4978 4.7574 0.176
JHOS-4 CTRP1 6.8184 9.1132 4.2423 2.5352
OVMANA CTRP1 7.3059 8.426 4.7024 0.0882
OVKATE CTRP1 8.1839 9.7139 7.8702 14.9895
RMUG-S CTRP1 8.2981 13.4443 6.2038 26.8121
JHOM-1 CTRP2; CTRP1 8.4306 10.0389 7.9812 5.9031
OVCAR-8 CTRP2; CTRP1 8.503 10.9738 7.6062 7.2641
OV56 CTRP2 9.0784 9.8522 8.6722 1.5327
COV362 CTRP2; CTRP1 9.1232 13.0763 7.1036 8.085
ONCO-DG-1 CTRP2 9.4937 13.4934 6.4388 4.8957
A2780 CTRP2; CTRP1 9.4945 11.942 7.9623 3.8302
SNU-8 CTRP2 9.5144 11.1788 7.497 0.7534
RMG-I CTRP2; CTRP1 9.59 13.0283 7.4976 5.6005
OAW42 CTRP2; CTRP1 9.6661 10.7769 8.6376 0.8851
JHOC-5 CTRP2; CTRP1 9.7589 13.7736 7.2564 6.3195
OVK18 CTRP2; CTRP1 9.771 15.2217 6.549 9.2152
Caov-3 CTRP2; CTRP1 9.7888 11.5595 8.3519 1.8211
OVCAR-4 CTRP2; CTRP1 9.9016 15.2231 6.6478 8.5888
MCAS CTRP2 10.0609 15.675 6.5375 8.7269
OAW28 CTRP2 10.0673 12.2915 8.1781 2.1027
FU-OV-1 CTRP2 10.2767 11.891 7.5494 0.2556
SNU-119 CTRP2 10.3418 15.1625 6.9918 6.4416
EFO-27 CTRP2; CTRP1 10.4413 14.0912 7.5805 3.9932
DOV13 CTRP2 10.5459 12.2542 8.4562 0.7056
ES2 CTRP2 10.6015 15.9419 6.7956 6.8463
OVISE CTRP2 10.6236 12.1592 8.5296 0.4657
SK-OV-3 CTRP2; CTRP1 10.6249 12.4717 8.4051 0.7995
TOV-21G CTRP2 10.7699 11.93 8.6738 0.1327
SNU-840 CTRP2; CTRP1 10.8335 14.3725 7.6949 3.0751
OVCAR-5 CTRP2 10.977 13.2281 8.2645 0.968
OVTOKO CTRP2 10.9805 13.2622 8.2521 1.0014
OVSAHO CTRP2 11.0026 12.4172 8.5883 0.2017
EFO-21 CTRP2; CTRP1 11.0636 12.3272 8.6426 0.1137
JHOS-2 CTRP2 11.0873 15.1985 7.4619 3.6137
COV434 CTRP2; CTRP1 11.0997 19.5601 5.3966 11.5588
TYK-nu CTRP2; CTRP1 11.1066 15.6758 7.2614 4.3891
TOV-112D CTRP2 11.2004 13.0775 8.4239 0.4414
IGROV-1 CTRP2; CTRP1 11.2346 17.2578 6.6 6.7722
COV644 CTRP2; CTRP1 11.4476 20.1215 5.3697 11.1304
HEY A8 CTRP2; CTRP1 11.5516 17.5396 6.6647 6.0688
Kuramochi CTRP2 11.7588 13.7691 8.3923 0.3076
OV-90 CTRP2; CTRP1 12.1794 19.0125 6.3799 6.4045
OV7 CTRP2; CTRP1 12.4162 19.3071 6.3888 6.0939
OC 314 CTRP2 14.8651 24.5911 5.4234 6.7531
⏷ Show the Full List of 45 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Thigh Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
H-STS CTRP2 9.868 12.6534 7.8759 3.5597
SYO-1 CTRP2 10.6705 12.3109 8.4909 0.5372
Cancer Drug Sensitivity Data Curated from 23 Cell Line(s) in Soft Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
Yamato-SS CTRP2 9.9635 11.8169 8.3333 1.6378
Aska-SS CTRP2 10.5446 11.7572 8.6492 0.2372
Rh41 CTRP2 9.0101 11.873 6.8889 3.691
BT-12 CTRP2 9.2341 10.6801 8.3827 2.4673
BT-16 CTRP2 9.7905 11.5446 8.3524 1.7717
RKN CTRP2; CTRP1 9.7997 13.059 7.6376 4.6824
KYM-1 CTRP2 9.9266 11.9405 8.2535 1.9845
GCT CTRP2 10.0401 14.0438 7.3223 5.5546
G-401 CTRP2; CTRP1 10.1713 15.8913 6.5128 8.6468
G-402 CTRP2 10.1986 15.6567 6.648 8.0553
SW982 CTRP2 10.388 11.5763 8.6527 0.2912
A-204 CTRP2 10.4313 16.2188 6.5413 8.1208
TE 441.T CTRP2 10.5517 11.9264 8.5884 0.3616
Tm87-16 CTRP2 10.6864 12.0556 8.5958 0.2899
MES-SA CTRP2 10.7771 12.4513 8.4832 0.5004
TTC-709 CTRP2 10.787 12.3431 8.5291 0.3893
HT-1080 CTRP2; CTRP1 11.0913 15.5104 7.3285 4.1528
RD CTRP2 11.1381 13.8224 8.0972 1.3534
TE 617.T CTRP2 11.309 12.7293 8.5921 0.1287
SK-UT-1 CTRP2 11.3164 13.6656 8.2464 0.8072
Rh18 CTRP2 12.0147 23.5638 4.0908 14.6391
SK-LMS-1 CTRP2 12.3237 21.0184 5.5246 9.3007
Hs 729.T CTRP2 14.2201 25.6789 4.5475 10.244
⏷ Show the Full List of 23 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Clivus Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
U-CH1 CTRP2 10.0436 11.8304 7.4777 0.4941
Cancer Drug Sensitivity Data Curated from 7 Cell Line(s) in Pleura Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MSTO-211H CTRP2; CTRP1 9.1959 12.0771 6.9147 3.3136
ACC-MESO-1 CTRP2 9.2098 10.6917 7.5493 0.8208
IST-Mes1 CTRP2 10.2616 13.9322 7.5297 4.3922
NCI-H2452 CTRP2 10.8713 29.0374 0.5305 25.6804
NCI-H2052 CTRP2; CTRP1 11.2541 12.6302 8.6065 0.1217
NCI-H28 CTRP2; CTRP1 11.3749 17.1848 6.7184 6.0889
JL-1 CTRP2 14.3761 30.5809 2.3344 16.4245
⏷ Show the Full List of 7 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 5 Cell Line(s) in Prostate Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
LNCaP clone FGC CTRP2 9.2252 10.9641 8.2346 3.1019
VCaP CTRP2 9.6403 12.0365 8.0154 3.331
PaCa-3 CTRP2; CTRP1 10.118 11.4732 8.57 0.6692
DU145 CTRP2 10.9649 13.3298 8.2166 1.1178
22Rv1 CTRP2 11.0896 15.2021 7.4616 3.6121
Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Salivary Gland Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
YD-15 CTRP2 10.8642 11.8084 8.7488 0.0417
A-253 CTRP2 10.9226 14.6407 7.618 3.2189
Cancer Drug Sensitivity Data Curated from 33 Cell Line(s) in Stomach Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
AGS CTRP2; CTRP1 8.3781 10.8403 7.5524 7.7739
GSU CTRP2 9.0099 9.85 7.7955 0.2274
ECC12 CTRP2 9.2508 10.8828 7.4892 0.99
GSS CTRP2 9.275 10.7116 7.5733 0.691
HuG1-N CTRP2 9.4073 12.6498 7.5384 5.6933
LMSU CTRP2 9.6875 11.6516 8.2344 2.374
23132/87 CTRP2 9.6918 11.2326 7.5565 0.4758
NUGC-3 CTRP2 9.8824 13.5537 7.4484 5.2818
MKN45 CTRP2 9.9592 11.3463 8.5416 0.8936
NUGC-4 CTRP2; CTRP1 9.9904 11.8772 7.4365 0.6255
HGC-27 CTRP2 10.2011 12.5065 8.1606 2.0125
SNU-601 CTRP2 10.2658 20.9562 4.0772 28.2861
SNU-620 CTRP2 10.3 11.4707 8.6556 0.3244
MKN74 CTRP2; CTRP1 10.3304 11.9846 8.4623 0.8405
SNU-1 CTRP2 10.5279 14.7462 7.3193 4.8627
SNU-668 CTRP2 10.5861 12.5121 8.3694 0.933
SNU-5 CTRP2 10.7029 11.9939 8.6252 0.228
MKN1 CTRP2 10.7635 12.2822 8.5424 0.3704
NCI-N87 CTRP2 10.8221 18.0524 5.9264 9.9411
Fu97 CTRP2; CTRP1 10.8968 15.9488 6.9915 5.6569
Hs 746.T CTRP2 11.1384 16.6051 6.8388 5.9318
MKN7 CTRP2; CTRP1 11.2913 12.9607 8.5036 0.2581
ECC10 CTRP2 11.2981 12.8231 8.5553 0.1777
IM95 CTRP2 11.5041 13.3822 8.4335 0.3136
SNU-719 CTRP2 11.505 12.9988 8.5695 0.1207
SNU-16 CTRP2 11.7855 20.429 5.4471 10.3167
NCC-StC-K140 CTRP2 11.933 14.0626 8.3536 0.3215
SH-10-TC CTRP2; CTRP1 12.4027 17.9949 6.9659 4.0099
KE-39 CTRP2 12.6966 18.9113 6.7244 4.5574
SNU-216 CTRP2 13.4077 24.954 4.3703 11.8067
SNU-685 CTRP2 9.695 11.2855 8.4131 1.6568
SNG-M CTRP2; CTRP1 10.8804 15.9034 7.0023 5.6366
SNU-1077 CTRP2 11.06 13.3537 8.2528 0.9461
⏷ Show the Full List of 33 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 12 Cell Line(s) in Thyroid Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
B-CPAP CTRP2 9.1927 12.1201 6.8923 3.4119
CGTH-W-1 CTRP2 9.5181 12.281 7.0197 2.4715
FTC-133 CTRP2 10.0658 12.1081 8.2616 1.7895
8305C CTRP2 10.1742 11.8118 7.5382 0.309
CAL-62 CTRP2 10.9237 12.0843 8.6762 0.0999
SW579 CTRP2 11.0526 14.1736 7.9017 2.0664
BHT-101 CTRP2 11.2305 21.156 4.704 13.7979
TT2609-C02 CTRP2 11.6379 13.5391 8.4286 0.2824
FTC-238 CTRP2 12.0861 19.3664 6.1491 7.3295
TT CTRP2 12.3897 22.7497 3.9477 10.6352
ML-1 [Human leukemia] CTRP2 12.6036 31.0189 0.868 22.3213
8505C CTRP2 13.5313 23.5397 5.112 9.2183
⏷ Show the Full List of 12 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 29 Cell Line(s) in Upper Aerodigestive Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SCC-9 CTRP2; CTRP1 8.7731 11.3857 7.6496 6.4932
BICR 18 CTRP2 9.5925 11.5866 8.2003 2.6485
Detroit 562 CTRP2 9.7702 11.5126 7.4816 0.6309
CAL-33 CTRP2 9.9935 11.6423 8.43 1.2505
BICR 31 CTRP2 10.0287 12.231 8.1822 2.1334
BICR 16 CTRP2 10.3022 11.9603 8.4582 0.8753
BICR 6 CTRP2 10.451 14.1506 7.5513 4.0502
SCC-25 CTRP2 10.5465 18.1616 5.6732 11.3528
FaDu CTRP2 10.6456 12.0524 8.5801 0.3388
HSC-3 CTRP2 10.7948 12.3228 8.5401 0.3621
SNU-1066 CTRP2 10.8115 12.6799 8.4085 0.6719
SNU-46 CTRP2 10.825 15.2286 7.2849 4.6058
YD-10B CTRP2 10.8338 12.3892 8.5312 0.3648
SNU-1076 CTRP2 10.8534 11.9903 8.6833 0.104
HSC-4 CTRP2 10.8991 12.7681 8.4132 0.6101
CAL-27 CTRP2 10.9233 12.0668 8.6821 0.0934
SCC-4 CTRP2 10.9349 15.9867 6.9985 5.5787
BICR 22 CTRP2 11.0013 12.3065 8.6271 0.1454
PE/CA-PJ49 CTRP2 11.0152 11.9875 8.7405 0.0345
BHY CTRP2 11.1192 12.5625 8.5806 0.1835
PE/CA-PJ41 (clone D2) CTRP2 11.158 12.4113 8.6474 0.0932
HSC-2 CTRP2; CTRP1 11.1744 16.1397 7.0803 4.9545
SNU-1214 CTRP2 11.2784 16.9418 6.7706 6.0126
SNU-899 CTRP2 11.3373 19.7303 5.475 10.8669
PE/CA-PJ15 CTRP2 11.3441 13.0283 8.4996 0.2497
YD-8 CTRP2 11.8387 19.1007 6.1152 7.7733
PE/CA-PJ34 (clone C12) CTRP2 11.8436 20.0547 5.6655 9.4365
BICR 56 CTRP2 12.1622 21.6882 5.0985 11.0332
SNU-1041 CTRP2 12.3611 18.0954 6.8976 4.2911
⏷ Show the Full List of 29 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 24 Cell Line(s) in Urinary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
639V CTRP2 8.7866 11.0747 7.1202 3.0353
253J CTRP2 9.04 12.3063 6.701 4.4539
JMSU-1 CTRP2 9.295 10.7685 7.5596 0.7195
5637 CTRP2; CTRP1 9.4387 14.2532 6.0368 6.6943
647V CTRP2 9.7472 11.9377 8.1376 2.6781
VM-CUB-1 CTRP2 9.9742 13.9429 6.5337 3.8561
SW1710 CTRP2 9.9742 13.9786 7.3069 5.7192
RT-4 CTRP2; CTRP1 10.0916 12.9818 7.8696 3.2726
RT-112 CTRP2 10.181 12.1845 8.2947 1.5426
HT-1376 CTRP2; CTRP1 10.3743 12.2486 8.3728 1.0907
BFTC-905 CTRP2 10.6275 12.2051 8.5133 0.5038
KU-19-19 CTRP2 10.7354 11.8116 8.7026 0.1028
U-BLC1 CTRP2 10.769 17.1796 6.3132 8.5125
HT-1197 CTRP2 10.8863 12.1433 8.6419 0.1507
253J-BV CTRP2 10.9395 12.633 8.4831 0.4241
UM-UC-1 CTRP2 11.0431 14.793 7.6202 3.0775
SCaBER CTRP2 11.3243 12.6309 8.6312 0.0855
CAL-29 CTRP2 11.3666 12.6433 8.6417 0.0712
J82 CTRP2 11.5278 13.1366 8.53 0.1626
T24 CTRP2 11.7604 13.3835 8.5284 0.1239
TCCSUP CTRP2 11.7654 18.0396 6.5662 6.1742
KMBC-2 CTRP2; CTRP1 12.0783 18.0857 6.7368 5.1723
UM-UC-3 CTRP2; CTRP1 12.2984 17.4016 7.1696 3.4074
BC-3C CTRP2 13.4347 24.8233 4.4496 11.5176
⏷ Show the Full List of 24 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Urogenital System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HeLa CTRP2 16.1693 32.5289 2.5802 13.653

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Rhucin
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Berotralstat DMWA2DZ Moderate Decreased metabolism of Rhucin caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [10]
Coadministration of a Drug Treating the Disease Different from Rhucin (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Moderate Increased metabolism of Rhucin caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [10]
Arn-509 DMT81LZ Moderate Increased metabolism of Rhucin caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [10]
Mitotane DMU1GX0 Moderate Increased metabolism of Rhucin caused by Mitotane mediated induction of CYP450 enzyme. Adrenal cancer [2D11] [10]
Ranolazine DM0C9IL Moderate Decreased metabolism of Rhucin caused by Ranolazine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [10]
Dronedarone DMA8FS5 Moderate Decreased metabolism of Rhucin caused by Dronedarone mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [10]
Butalbital DM9J04X Moderate Increased metabolism of Rhucin caused by Butalbital mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [10]
Methylphenobarbital DMDSWAG Moderate Increased metabolism of Rhucin caused by Methylphenobarbital mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [10]
Voriconazole DMAOL2S Major Decreased metabolism of Rhucin caused by Voriconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [11]
Zafirlukast DMHNQOG Moderate Decreased metabolism of Rhucin caused by Zafirlukast mediated inhibition of CYP450 enzyme. Asthma [CA23] [10]
Ciprofloxacin XR DM2NLS9 Moderate Decreased metabolism of Rhucin caused by Ciprofloxacin XR mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [10]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Rhucin caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [12]
Clarithromycin DM4M1SG Major Decreased metabolism of Rhucin caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [11]
Chloramphenicol DMFXEWT Moderate Decreased metabolism of Rhucin caused by Chloramphenicol mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [10]
Linezolid DMGFPU2 Moderate Additive hypotensive effects by the combination of Rhucin and Linezolid. Bacterial infection [1A00-1C4Z] [13]
Troleandomycin DMUZNIG Major Decreased metabolism of Rhucin caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [11]
Telithromycin DMZ4P3A Major Decreased metabolism of Rhucin caused by Telithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [11]
Erdafitinib DMI782S Moderate Increased metabolism of Rhucin caused by Erdafitinib mediated induction of CYP450 enzyme. Bladder cancer [2C94] [14]
Pexidartinib DMS2J0Z Moderate Increased metabolism of Rhucin caused by Pexidartinib mediated induction of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [10]
Lapatinib DM3BH1Y Moderate Decreased metabolism of Rhucin caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [10]
Tucatinib DMBESUA Major Decreased metabolism of Rhucin caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [11]
Palbociclib DMD7L94 Moderate Decreased metabolism of Rhucin caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [10]
Alpelisib DMEXMYK Moderate Increased metabolism of Rhucin caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [15]
Grepafloxacin DMGLX0T Moderate Decreased metabolism of Rhucin caused by Grepafloxacin mediated inhibition of CYP450 enzyme. Bronchitis [CA20] [10]
Secobarbital DM14RF5 Moderate Increased metabolism of Rhucin caused by Secobarbital mediated induction of CYP450 enzyme. Chronic insomnia [7A00] [10]
Phenylbutazone DMAYL0T Moderate Increased metabolism of Rhucin caused by Phenylbutazone mediated induction of CYP450 enzyme. Chronic pain [MG30] [10]
Anisindione DM2C48U Moderate Increased risk of bleeding by the combination of Rhucin and Anisindione. Coagulation defect [3B10] [16]
Mifepristone DMGZQEF Moderate Decreased metabolism of Rhucin caused by Mifepristone mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [11]
Aminoglutethimide DMWFHMZ Moderate Increased metabolism of Rhucin caused by Aminoglutethimide mediated induction of CYP450 enzyme. Cushing syndrome [5A70] [10]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Rhucin caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [10]
Ethanol DMDRQZU Moderate Additive hypotensive effects by the combination of Rhucin and Ethanol. Cystitis [GC00] [16]
Aprepitant DM053KT Moderate Decreased metabolism of Rhucin caused by Aprepitant mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [10]
Nefazodone DM4ZS8M Major Decreased metabolism of Rhucin caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [11]
Selegiline DM6034S Moderate Additive hypotensive effects by the combination of Rhucin and Selegiline. Depression [6A70-6A7Z] [13]
Isocarboxazid DMAF1NB Moderate Additive hypotensive effects by the combination of Rhucin and Isocarboxazid. Depression [6A70-6A7Z] [13]
Tranylcypromine DMGB5RE Moderate Additive hypotensive effects by the combination of Rhucin and Tranylcypromine. Depression [6A70-6A7Z] [13]
Phenelzine DMHIDUE Moderate Additive hypotensive effects by the combination of Rhucin and Phenelzine. Depression [6A70-6A7Z] [13]
Griseofulvin DMK54YG Moderate Increased metabolism of Rhucin caused by Griseofulvin mediated induction of CYP450 enzyme. Dermatophytosis [1F28] [10]
Primidone DM0WX6I Moderate Increased metabolism of Rhucin caused by Primidone mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [10]
Felbamate DM1V5ZS Moderate Increased metabolism of Rhucin caused by Felbamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [10]
Oxcarbazepine DM5PU6O Moderate Increased metabolism of Rhucin caused by Oxcarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [10]
Cenobamate DM8KLU9 Moderate Increased metabolism of Rhucin caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [10]
Phenytoin DMNOKBV Moderate Increased metabolism of Rhucin caused by Phenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [10]
Fosphenytoin DMOX3LB Moderate Increased metabolism of Rhucin caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [10]
Phenobarbital DMXZOCG Moderate Increased metabolism of Rhucin caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [10]
Carbamazepine DMZOLBI Moderate Increased metabolism of Rhucin caused by Carbamazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [10]
Tazemetostat DMWP1BH Moderate Increased metabolism of Rhucin caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [10]
Itraconazole DMCR1MV Major Decreased metabolism of Rhucin caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [11]
Clotrimazole DMMFCIH Moderate Decreased metabolism of Rhucin caused by Clotrimazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [10]
Miconazole DMPMYE8 Moderate Decreased metabolism of Rhucin caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [17]
Ketoconazole DMPZI3Q Major Decreased metabolism of Rhucin caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [11]
Cimetidine DMH61ZB Moderate Decreased metabolism of Rhucin caused by Cimetidine mediated inhibition of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [10]
Sulfinpyrazone DMEV954 Moderate Increased metabolism of Rhucin caused by Sulfinpyrazone mediated induction of CYP450 enzyme. Gout [FA25] [10]
Boceprevir DMBSHMF Major Decreased metabolism of Rhucin caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [18]
Simeprevir DMLUA9D Moderate Decreased metabolism of Rhucin caused by Simeprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [19]
Telaprevir DMMRV29 Major Decreased metabolism of Rhucin caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [18]
Isoniazid DM5JVS3 Moderate Decreased metabolism of Rhucin caused by Isoniazid mediated inhibition of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [10]
Rifampin DMA8J1G Moderate Increased metabolism of Rhucin caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [10]
Rifapentine DMCHV4I Moderate Increased metabolism of Rhucin caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [10]
Procarbazine DMIK367 Moderate Additive hypotensive effects by the combination of Rhucin and Procarbazine. Hodgkin lymphoma [2B30] [13]
Indinavir DM0T3YH Major Decreased metabolism of Rhucin caused by Indinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [18]
Delavirdine DM3NF5G Major Decreased metabolism of Rhucin caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [11]
Fosamprenavir DM4W9B3 Major Decreased metabolism of Rhucin caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [18]
Nevirapine DM6HX9B Moderate Increased metabolism of Rhucin caused by Nevirapine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [10]
Cobicistat DM6L4H2 Major Decreased metabolism of Rhucin caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [20]
Efavirenz DMC0GSJ Moderate Increased metabolism of Rhucin caused by Efavirenz mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [10]
Saquinavir DMG814N Major Decreased metabolism of Rhucin caused by Saquinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [18]
Etravirine DMGV8QU Moderate Increased metabolism of Rhucin caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [21]
Amprenavir DMLMXE0 Major Decreased metabolism of Rhucin caused by Amprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [18]
Darunavir DMN3GCH Major Decreased metabolism of Rhucin caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [18]
Atazanavir DMSYRBX Major Decreased metabolism of Rhucin caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [18]
Ritonavir DMU764S Major Decreased metabolism of Rhucin caused by Ritonavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [18]
BMS-201038 DMQTAGO Moderate Decreased metabolism of Rhucin caused by BMS-201038 mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [10]
Conivaptan DM1V329 Moderate Decreased metabolism of Rhucin caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [20]
Suvorexant DM0E6S3 Moderate Decreased metabolism of Rhucin caused by Suvorexant mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [10]
Amobarbital DM0GQ8N Moderate Increased metabolism of Rhucin caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [10]
Butabarbital DMC5AST Moderate Increased metabolism of Rhucin caused by Butabarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [10]
Pentobarbital DMFNH7L Moderate Increased metabolism of Rhucin caused by Pentobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [10]
Crizotinib DM4F29C Moderate Decreased metabolism of Rhucin caused by Crizotinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [10]
Brigatinib DM7W94S Moderate Increased metabolism of Rhucin caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [22]
Ceritinib DMB920Z Major Decreased metabolism of Rhucin caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [11]
PF-06463922 DMKM7EW Moderate Increased metabolism of Rhucin caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [10]
Selpercatinib DMZR15V Moderate Decreased metabolism of Rhucin caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [10]
Idelalisib DM602WT Major Decreased metabolism of Rhucin caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [11]
IPI-145 DMWA24P Moderate Decreased metabolism of Rhucin caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [10]
Vemurafenib DM62UG5 Moderate Increased metabolism of Rhucin caused by Vemurafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [10]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Rhucin caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [10]
Danazol DML8KTN Moderate Decreased metabolism of Rhucin caused by Danazol mediated inhibition of CYP450 enzyme. Menstrual cycle bleeding disorder [GA20] [10]
Exjade DMHPRWG Moderate Decreased metabolism of Rhucin caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [23]
Ozanimod DMT6AM2 Moderate Additive hypotensive effects by the combination of Rhucin and Ozanimod. Multiple sclerosis [8A40] [13]
Rifabutin DM1YBHK Moderate Increased metabolism of Rhucin caused by Rifabutin mediated induction of CYP450 enzyme. Mycobacterium infection [1B10-1B21] [10]
Bexarotene DMOBIKY Moderate Increased metabolism of Rhucin caused by Bexarotene mediated induction of CYP450 enzyme. Mycosis fungoides [2B01] [10]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Rhucin caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [10]
Nilotinib DM7HXWT Moderate Decreased metabolism of Rhucin caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [10]
Imatinib DM7RJXL Moderate Decreased metabolism of Rhucin caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [10]
Modafinil DMYILBE Minor Increased metabolism of Rhucin caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [24]
Netupitant DMEKAYI Moderate Decreased metabolism of Rhucin caused by Netupitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [12]
Entrectinib DMMPTLH Moderate Decreased metabolism of Rhucin caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [10]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Rhucin caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [10]
Safinamide DM0YWJC Moderate Additive hypotensive effects by the combination of Rhucin and Safinamide. Parkinsonism [8A00] [13]
Rasagiline DM3WKQ4 Moderate Additive hypotensive effects by the combination of Rhucin and Rasagiline. Parkinsonism [8A00] [13]
Abametapir DM2RX0I Moderate Decreased metabolism of Rhucin caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [25]
Lefamulin DME6G97 Moderate Decreased metabolism of Rhucin caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [26]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Rhucin caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [11]
Enzalutamide DMGL19D Moderate Increased metabolism of Rhucin caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [10]
Bicalutamide DMZMSPF Moderate Decreased metabolism of Rhucin caused by Bicalutamide mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [10]
Bosentan DMIOGBU Moderate Decreased metabolism of Rhucin caused by Bosentan mediated inhibition of CYP450 enzyme. Pulmonary hypertension [BB01] [12]
Temsirolimus DMS104F Moderate Increased plasma concentrations of Rhucin and Temsirolimus due to competitive inhibition of the same metabolic pathway. Renal cell carcinoma [2C90] [27]
Dexamethasone DMMWZET Moderate Increased metabolism of Rhucin caused by Dexamethasone mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [10]
Nafcillin DMN9RPO Moderate Increased metabolism of Rhucin caused by Nafcillin mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [10]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Rhucin caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [10]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Rhucin caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [16]
Larotrectinib DM26CQR Moderate Decreased metabolism of Rhucin caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [10]
Armodafinil DMGB035 Minor Increased metabolism of Rhucin caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [24]
LEE011 DMMX75K Moderate Decreased metabolism of Rhucin caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [10]
Warfarin DMJYCVW Moderate Increased risk of bleeding by the combination of Rhucin and Warfarin. Supraventricular tachyarrhythmia [BC81] [16]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Rhucin caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [28]
Brilinta DMBR01X Moderate Decreased metabolism of Rhucin caused by Brilinta mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [10]
Dicumarol DMFQCB1 Moderate Increased risk of bleeding by the combination of Rhucin and Dicumarol. Thrombosis [DB61-GB90] [16]
Sirolimus DMGW1ID Moderate Increased plasma concentrations of Rhucin and Sirolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [27]
Tacrolimus DMZ7XNQ Moderate Increased plasma concentrations of Rhucin and Tacrolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [29]
Elagolix DMB2C0E Moderate Increased metabolism of Rhucin caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [10]
Amiodarone DMUTEX3 Moderate Decreased metabolism of Rhucin caused by Amiodarone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [10]
⏷ Show the Full List of 122 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
FD&C blue no. 2 E00446 2723854 Colorant
Sodium stearyl fumarate E00545 23665634 lubricant
Sunset yellow FCF E00255 17730 Colorant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Brushite E00392 104805 Diluent
Calcium hydrogenphosphate E00294 24441 Diluent
Carmellose sodium E00625 Not Available Disintegrant
Crospovidone E00626 Not Available Disintegrant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 3350 E00652 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 4000 E00654 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
⏷ Show the Full List of 17 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Sildenafil 100 mg tablet 100 mg Oral Tablet Oral
Sildenafil 25 mg tablet 25 mg Oral Tablet Oral
Sildenafil 50 mg tablet 50 mg Oral Tablet Oral
Sildenafil 20 mg tablet 20 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4743).
2 Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
3 cGMP-hydrolytic activity and its inhibition by sildenafil in normal and failing human and mouse myocardium. J Pharmacol Exp Ther. 2009 Sep;330(3):884-91.
4 Inhibition of cGMP-specific phosphodiesterase type 5 reduces sodium excretion and arterial blood pressure in patients with NaCl retention and ascites. Am J Physiol Renal Physiol. 2005 May;288(5):F1044-52. doi: 10.1152/ajprenal.00142.2004. Epub 2004 Dec 21.
5 Sildenafil increases chemotherapeutic efficacy of doxorubicin in prostate cancer and ameliorates cardiac dysfunction. Proc Natl Acad Sci U S A. 2010 Oct 19;107(42):18202-7. doi: 10.1073/pnas.1006965107. Epub 2010 Sep 30.
6 Sildenafil ameliorates effects of inhaled nitric oxide withdrawal. Anesthesiology. 1999 Jul;91(1):307-10. doi: 10.1097/00000542-199907000-00041.
7 Adenosine receptors and phosphodiesterase inhibitors stimulate Cl- secretion in Calu-3 cells. Am J Respir Cell Mol Biol. 2003 Sep;29(3 Pt 1):410-8. doi: 10.1165/rcmb.2002-0247OC. Epub 2003 Apr 24.
8 Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
9 Efficacy of oral sildenafil in a beraprost-treated patient with severe pulmonary hypertension secondary to type I glycogen storage disease. Circ J. 2009 Oct;73(10):1965-8. doi: 10.1253/circj.cj-08-0181. Epub 2009 Jan 27.
10 Hyland R, Roe GH, Jones BC, Smith DA "Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil." Br J Clin Pharmaacol 51 (2001): 239-48. [PMID: 11298070]
11 Cerner Multum, Inc. "Australian Product Information.".
12 Product Information. Revatio (sildenafil). Pfizer U.S. Pharmaceuticals Group, New York, NY.
13 Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
14 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
15 Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
16 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
17 Product Information. ORAVIG (miconazole). Strativa Pharmaceuticals, a Division of Par Pharmaceuticals, Inc., Woodcliff Lake, NJ.
18 Barry M, Mulcahy F, Merry C, Gibbons S, Back D "Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection." Clin Pharmacokinet 36 (1999): 289-304. [PMID: 10320951]
19 Product Information. Olysio (simeprevir). Janssen Pharmaceuticals, Titusville, NJ.
20 Hall MCS, Ahmad S "Interaction between sildenafil and HIV-1 combination therapy." Lancet 353 (1999): 2071-2. [PMID: 10376645]
21 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
22 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
23 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
24 Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
25 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
26 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
27 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
28 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
29 Christ B, Brockmeier D, Hauck EW, Friemann S "Interactions of sildenafil and tacrolimus in men with erectile dysfunction after kidney transplantation." Urology 58 (2001): 589-93. [PMID: 11597545]